share_log

藥明康德：翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

香港交易所 ·  Mar 22 06:18
Summary by Moomoo AI
無錫藥明康德新藥開發股份有限公司（药明康德）於2024年3月8日至3月22日期間，通過上海證券交易所回購共計3,607,862股A股股份，佔其已發行股份的約0.14%。該公司股份回購的價格範圍在RMB 48.22至RMB 57.32之間，並於3月22日以RMB 38.62的價格根據2019年A股激勵計劃行使股票期權，發行了23,985股A股普通股。根據香港聯合交易所有限公司證券上市規則，公司已於3月22日呈交翌日披露報表，確認所有相關法律規定已遵行，並已收取全部款項。股份回購後，公司的已發行股本為2,546,203,143股。
無錫藥明康德新藥開發股份有限公司（药明康德）於2024年3月8日至3月22日期間，通過上海證券交易所回購共計3,607,862股A股股份，佔其已發行股份的約0.14%。該公司股份回購的價格範圍在RMB 48.22至RMB 57.32之間，並於3月22日以RMB 38.62的價格根據2019年A股激勵計劃行使股票期權，發行了23,985股A股普通股。根據香港聯合交易所有限公司證券上市規則，公司已於3月22日呈交翌日披露報表，確認所有相關法律規定已遵行，並已收取全部款項。股份回購後，公司的已發行股本為2,546,203,143股。
WUXI PHARMACEUTICAL MING KAND NEW DRUG DEVELOPMENT CO., LTD. (PHARMACEUTICAL MING KAND) FROM MARCH 8 TO MARCH 22, 2024, REPURCHASED A TOTAL OF 3,607,862 SHARES OF A-SHARES THROUGH THE SHANGHAI STOCK EXCHANGE, REPRESENTING APPROXIMATELY 0.14% OF ITS ISSUED SHARES. THE COMPANY'S SHARE REPURCHASE RANGED FROM RMB 48.22 TO RMB 57.32 AND ON MARCH 22 AT A PRICE OF RMB 38.62, EXERCISING STOCK OPTIONS UNDER THE 2019 A-SHARE INCENTIVE SCHEME, ISSUED 23,985 SHARES OF A-SHARE ORDINARY SHARES. Pursuant to the Listing Rules of the Stock Exchange of Hong Kong Limited, the Company filed the following day's disclosure statement on 22 March, confirming that all relevant legal requirements have been complied with and that all monies have been collected. After the share repurchase, the issued share capital of the company is 2,546,203,143 shares.
WUXI PHARMACEUTICAL MING KAND NEW DRUG DEVELOPMENT CO., LTD. (PHARMACEUTICAL MING KAND) FROM MARCH 8 TO MARCH 22, 2024, REPURCHASED A TOTAL OF 3,607,862 SHARES OF A-SHARES THROUGH THE SHANGHAI STOCK EXCHANGE, REPRESENTING APPROXIMATELY 0.14% OF ITS ISSUED SHARES. THE COMPANY'S SHARE REPURCHASE RANGED FROM RMB 48.22 TO RMB 57.32 AND ON MARCH 22 AT A PRICE OF RMB 38.62, EXERCISING STOCK OPTIONS UNDER THE 2019 A-SHARE INCENTIVE SCHEME, ISSUED 23,985 SHARES OF A-SHARE ORDINARY SHARES. Pursuant to the Listing Rules of the Stock Exchange of Hong Kong Limited, the Company filed the following day's disclosure statement on 22 March, confirming that all relevant legal requirements have been complied with and that all monies have been collected. After the share repurchase, the issued share capital of the company is 2,546,203,143 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more